Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CorMedix Inc.
  6. News
  7. Summary
    CRMD   US21900C3088

CORMEDIX INC.

(CRMD)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
4.450 USD   +3.73%
11/10Transcript : CorMedix Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10CORMEDIX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
11/10CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference

09/07/2022 | 08:31am EST

BERKELEY HEIGHTS, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will be presenting a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in New York on September 12 – 14, 2022.

H.C. Wainwright Annual Global Investment Conference

Date:        Monday, September 12, 2022
Time:        12:30pm EDT
Webcast Link

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the original New Drug Application (NDA) received priority review in recognition of its potential to address an unmet medical need. QIDP provides for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using a central venous catheter for hemodialysis when the NDA is approved, which will add an additional six months of marketing exclusivity when the study is completed. The Company received a Complete Response Letter (CRL) from FDA stating that the original NDA could not be approved until deficiencies at the contract manufacturing organization (CMO) were satisfactorily resolved. FDA notified the Company in a second CRL that the refiled NDA could not be approved until satisfactory resolution of deficiencies identified during a pre-approval inspection at the CMO and during an inspection for an unrelated active pharmaceutical ingredient at the manufacturing facility for the heparin supplier for DefenCath. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with plans for programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
(617) 430-7576


Primary Logo

Source: CorMedix, Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about CORMEDIX INC.
11/10Transcript : CorMedix Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10CORMEDIX INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/10Cormedix : Q3 Earnings Snapshot
AQ
11/10Earnings Flash (CRMD) CORMEDIX Posts Q3 Revenue $6,817
MT
11/10CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
AQ
11/10North American Morning Briefing: Crucial -3-
DJ
11/07CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath
AQ
11/02CorMedix Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Up..
AQ
10/21Cormedix Inc. : Changes in Registrant's Certifying Accountant, Financial Statements and Ex..
AQ
More news
Analyst Recommendations on CORMEDIX INC.
More recommendations
Financials (USD)
Sales 2022 0,01 M - -
Net income 2022 -29,5 M - -
Net cash 2022 52,2 M - -
P/E ratio 2022 -6,10x
Yield 2022 -
Capitalization 184 M 184 M -
EV / Sales 2022 9 173x
EV / Sales 2023 27,5x
Nbr of Employees 30
Free-Float 98,7%
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORMEDIX INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,45 $
Average target price 15,00 $
Spread / Average Target 237%
EPS Revisions
Managers and Directors
Joseph Todisco Chief Executive Officer & Director
Mathew T. David Chief Financial Officer & Executive Vice President
Myron Lawrence Kaplan Chairman
Antony E. Pfaffle Secretary & Chief Scientific Officer
Elizabeth Masson-Hurlburt Executive VP-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CORMEDIX INC.-5.71%184
MERCK KGAA-21.87%80 851
KYOWA KIRIN CO. LTD.-0.48%12 391
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD-30.86%4 623
SK BIOPHARMACEUTICALS CO., LTD.-25.41%4 353
YUHAN CORPORATION-6.12%3 045